# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for ...
Stifel analyst Bradley Canino maintains Nuvalent (NASDAQ:NUVL) with a Buy and raises the price target from $103 to $115.
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their ...
Wedbush analyst David Nierengarten reiterates Nuvalent (NASDAQ:NUVL) with a Outperform and maintains $99 price target.
Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.68) by...